☆ 4.5 Article

Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma

PIGMENT CELL & MELANOMA RESEARCH (2018)

获取全文
添加到收藏夹

期刊

PIGMENT CELL & MELANOMA RESEARCH
卷 31, 期 3, 页码 404-410

出版社

WILEY
DOI: 10.1111/pcmr.12675

关键词

immune-related response criteria; immunotherapy; melanoma; pembrolizumab; programmed-death receptor 1

类别

Oncology Cell Biology Dermatology

向作者/读者索取更多资源

Protocol

社区支持

Reagent

社区支持

This study evaluated patterns of response as discerned by comprehensive metastasis-specific analysis in metastatic melanoma patients receiving anti-PD-1 antibodies. Bi-dimensional measurements of every metastasis in patients enrolled in the KEYNOTE-001 trial at a single institution were obtained at baseline and throughout treatment. Twenty-seven evaluable patients had 399 baseline metastases measurable on CT imaging. Complete response (CR) which occurred in 52.6% of metastases was smaller (mean 223 mm(2) versus 760 mm(2), p < .01) and occurred more frequently in the lungs (65% versus 39.4%, p < .01). Response was heterogenous (new/progressing metastases alongside CR metastases) at first assessment in 4/14 patients with objective response (OR) as opposed to 7/13 patients with non-OR. CR of individual metastases is common and influenced by site and size. Most patients with OR demonstrate homogenous regression in all metastases at the first assessment. In contrast, patients with early heterogeneity had a poor outcome.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Hypofractionated or Conventionally Fractionated Adjuvant Radiotherapy After Regional Lymph Node Dissection for High-Risk Stage III Melanoma

L. H. J. Holtkamp, S. Lo, M. Drummond, J. F. Thompson, O. E. Nieweg, A. M. Hong

Summary: This study compares the oncological outcomes of hypofractionated and conventionally fractionated adjuvant radiotherapy in high-risk stage III melanoma patients. The results show that overall survival, recurrence-free survival, and lymph node field control rates were similar between the two methods before effective systemic immunotherapy became available. Extranodal spread and an increasing number of positive lymph nodes were associated with unfavorable outcomes.

CLINICAL ONCOLOGY (2023)

添加到收藏夹
Article Oncology

Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation

Alison M. Weppler, Laetitia Da Meda, Ines Pires da Silva, Wen Xu, Giovanni Grignani, Alexander M. Menzies, Matteo S. Carlino, Georgina Long, Serigne N. Lo, Ina Nordman, Christopher B. Steer, Megan Lyle, Claudia Trojaniello, Paolo A. Ascierto, Celeste Lebbe, Shahneen Sandhu

Summary: The response to immune checkpoint inhibitors (ICIs) in metastatic Merkel cell carcinoma (mMCC) is not durable off treatment, but retreatment shows promising results.

EUROPEAN JOURNAL OF CANCER (2023)

添加到收藏夹
Article Oncology

BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes

Joanna Lee, Tasnia Ahmed, Andrea Maurichi, Lorenzo Di Guardo, Anna M. Stagno, Lydia Warburton, Amelia. M. Taylor, Elisabeth Livingstone, Saba Rehman, Adnan Khattak, Katharina C. Kahler, Vito Vanella, Victoria Atkinson, Michael Millward, Dirk Schadendorf, Douglas B. Johnson, Paolo A. Ascierto, Axel Hauschild, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies, Matteo S. Carlino

Summary: For patients with advanced melanoma, there is a risk of recurrence after discontinuation of targeted therapy, but retreatment with targeted therapy shows a high response rate.

EUROPEAN JOURNAL OF CANCER (2023)

添加到收藏夹
Article Dermatology

Melanomas in children and adolescents: Clinicopathologic features and survival outcomes

Mary-Ann El Sharouni, Robert Rawson, Alison J. Potter, Elizabeth C. Paver, James S. Wilmott, Arjen J. Witkamp, Vigfus Sigurdsson, Paul J. van Diest, Richard A. Scolyer, John F. Thompson, Serigne N. Lo, Carla H. van Gils

Summary: This study evaluated the clinicopathological features and survival of children and adolescents diagnosed with melanoma. The study found that the 10-year recurrence-free survival rates for children and adolescents were 91.5% and 86.4% respectively, with no significant difference. Ulceration status and anatomic site were associated with recurrence-free survival and overall survival.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2023)

添加到收藏夹
Review Oncology

Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now

Georgina V. Long, Alexander M. Menzies, Richard A. Scolyer

Summary: The role of neoadjuvant therapy is shifting in oncology, from reducing surgical morbidity to a life-saving treatment with curative promise. Recent studies suggest that checkpoint inhibitors administered in the neoadjuvant setting may have greater clinical efficacy compared to the adjuvant setting.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹
Article Oncology

Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium

Talal El Zarif, Amin H. Nassar, Elio Adib, Bailey G. Fitzgerald, Jiaming Huang, Tarek H. Mouhieddine, Paul G. Rubinstein, Taylor Nonato, Rana R. McKay, Mingjia Li, Arjun Mittra, Dwight H. Owen, Robert A. Baiocchi, Michael Lorentsen, Christopher Dittus, Nazli Dizman, Adewunmi Falohun, Noha Abdel-Wahab, Adi Diab, Anand Bankapur, Alexandra Reed, Chul Kim, Aakriti Arora, Neil J. Shah, Edward El-Am, Elie Kozaily, Wassim Abdallah, Ahmad Al-Hader, Batool Abu Ghazal, Anwaar Saeed, Claire Drolen, Melissa G. Lechner, Alexandra Drakaki, Javier Baena, Caroline A. Nebhan, Tarek Haykal, Michael A. Morse, Alessio Cortellini, David J. Pinato, Alessia Dalla Pria, Evan Hall, Veli Bakalov, Nathan Bahary, Aarthi Rajkumar, Ankit Mangla, Vishal Shah, Parminder Singh, Frank Aboubakar Nana, Nerea Lopetegui-Lia, Danai Dima, Ryan W. Dobbs, Pauline Funchain, Rabia Saleem, Rachel Woodford, Georgina V. Long, Alexander M. Menzies, Carlo Genova, Giulia Barletta, Sonam Puri, Vaia Florou, Dame Idossa, Maristella Saponara, Paola Queirolo, Giuseppe Lamberti, Alfredo Addeo, Melissa Bersanelli, Dory Freeman, Wanling Xie, Erin G. Reid, Elizabeth Y. Chiao, Elad Sharon, Douglas B. Johnson, Ramya Ramaswami, Mark Bower, Brinda Emu, Thomas U. Marron, Toni K. Choueiri, Lindsey R. Baden, Kathryn Lurain, Guru P. Sonpavde, Abdul Rafeh Naqash

Summary: Compared with people living without HIV, people living with HIV and cancer have been excluded from immune checkpoint inhibitor trials. There is also a lack of real-world data on the use of ICIs in this population.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹
Article Oncology

Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations

Benjamin C. C. Park, Sathya Narayanan, Alexander Gavraldis, Fei Ye, Run Fan, Ryan J. J. Sullivan, Genevieve Boland, Kerry L. Reynolds, Justin M. M. Balko, Matteo S. S. Carlino, Georgina V. V. Long, Leyre Zubiri, Alexander M. M. Menzies, Douglas B. B. Johnson

Summary: Immune-related adverse events (irAEs) are side effects of immune checkpoint inhibitor therapy (ICI). The characterization of rare immune related adverse events (RirAEs) is limited, making accurate diagnosis and management difficult.

ONCOIMMUNOLOGY (2023)

添加到收藏夹
Article Oncology

Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy

Prachi Bhave, Angela Hong, Serigne N. Lo, Rebecca Johnson, Johanna Mangana, Douglas B. Johnson, Ozgecan Dulgar, Zeynep Eroglu, Hui-Ling Yeoh, Andrew Haydon, Georg C. Lodde, Elisabeth Livingstone, Adnan Khattak, Katharina Kaehler, Axel Hausschild, Grant A. McArthur, Alexander Maxwell Menzies, Georgina Long, Wei Wang, Matteo S. Carlino

Summary: This study investigates the role of adjuvant radiation therapy (RT) in patients with melanoma who experience locoregional disease recurrence during or after adjuvant anti-PD-1-based immunotherapy. The results show that adjuvant RT is associated with improved locoregional disease control, but does not affect the risk of distant recurrence.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

添加到收藏夹
Review Dermatology

Risk factors for subsequent primary melanoma in patients with previous melanoma: a systematic review and meta-analysis

Juliet Smith, Anne E. Cust, Serigne N. Lo

Summary: Compared with the general population, people with a previous melanoma are at increased risk of developing another primary melanoma. Several consistent, independent risk factors for subsequent primary melanoma have been identified, including male sex, increasing age, light skin, family history of melanoma, CDKN2A mutation, a high or moderate naevus count, atypical naevi, first lesions occurring on the head and neck, lentigo maligna subtype, other subtype and inadequate sun protection.

BRITISH JOURNAL OF DERMATOLOGY (2023)

添加到收藏夹
Article Oncology

Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results

Adi Diab, Helen Gogas, Shahneen Sandhu, Georgina V. Long, Paolo A. Ascierto, James Larkin, Mario Sznol, Fabio Franke, Tudor E. Ciuleanu, Caio Pereira, Eva Munoz Couselo, Fernanda Bronzon Damian, Michael Schenker, Aldo Perfetti, Celeste Lebbe, Gaelle Quereux, Friedegund Meier, Brendan D. Curti, Carlos Rojas, Yull Arriaga, Haisu Yang, Ming Zhou, Shruthi Ravimohan, Paul Statkevich, Mary A. Tagliaferri, Nikhil I. Khushalani

Summary: Despite the efficacy of Bempegaldesleukin (BEMPEG) in the treatment of melanoma, the PIVOT IO 001 study did not meet its primary end points, with increased toxicity observed with the combination of BEMPEG plus NIVO.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹
Article Dermatology

Prognostic Significance of Incipient Ulceration in Primary Cutaneous Melanoma

Elizabeth C. Paver, Tasnia Ahmed, Hazel Burke, Robyn P. M. Saw, Jonathan R. Stretch, Andrew J. Spillane, Kerwin F. Shannon, Ismael A. Vergara, David E. Elder, Serigne N. Lo, John F. Thompson, Richard A. Scolyer

Summary: Ulceration is a key feature in cutaneous melanoma and contributes to staging. However, cases with incipient ulceration do not meet the definition of ulceration and are classified as nonulcerated, leading to interpretive difficulty. The prognostic significance of incipient ulceration in cutaneous melanoma is uncertain.

JAMA DERMATOLOGY (2023)

添加到收藏夹
Article Oncology

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3+anti-PD-1-based immunotherapies

Tuba N. Gide, Elizabeth C. Paver, Zarwa Yaseen, Nigel Maher, Nurudeen Adegoke, Alexander M. Menzies, Ines Pires da Silva, James S. Wilmott, Georgina V. Long, Richard A. Scolyer

Summary: This study evaluated the association between LAG-3 expression and clinical outcomes in metastatic melanoma patients treated with anti-LAG-3 and anti-PD-1 immunotherapy. The results showed that LAG-3 expression was related to treatment response and tumor-infiltrating lymphocytes, and patients with ≥ 1% LAG-3+ cells had longer progression-free survival.

ONCOIMMUNOLOGY (2023)

添加到收藏夹
Article Oncology

Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence

Esmee P. Hoefsmit, Franziska Vollmy, Elisa A. Rozeman, Irene L. M. Reijers, Judith M. Versluis, Liesbeth Hoekman, Alexander C. J. van Akkooi, Georgina Long, Dirk Schadendorf, Reinhard Dummer, Maarten Altelaar, Christian U. Blank

Summary: Taking into account the higher response rates of neoadjuvant immune checkpoint blockade (ICB) in stage III melanoma compared to stage IV disease, researchers hypothesized that systemic immune suppression may be responsible for lower response rates and disease recurrence. Through proteomic profiling, they found that the protein LRG1 is associated with worse prognosis and can serve as a biomarker for identifying high-risk patients and as a potential target for neoadjuvant ICB therapy.

CANCER RESEARCH COMMUNICATIONS (2023)

添加到收藏夹
Article Oncology

The features and management of acquired resistance to PD1-based therapy in metastatic melanoma

Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies

Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.

EUROPEAN JOURNAL OF CANCER (2024)

添加到收藏夹
Article Oncology

Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging

Caroline A. Gjorup, Rachel Woodford, Isabel Li, Matteo S. Carlino, Sydney Ch'ng, David Chung, Edward Hsiao, Serigne N. Lo, Kevin London, Georgina V. Long, Alexander M. Menzies, Omgo E. Nieweg, Thomas E. Pennington, Michael A. Rtshiladze, Robyn P. M. Saw, Richard A. Scolyer, Kerwin F. Shannon, Andrew J. Spillane, Jonathan R. Stretch, John F. Thompson, Alexander H. R. Varey, Alexander C. J. van Akkooi

Summary: Routine concurrent ultrasound surveillance may be unnecessary for sentinel node-positive melanoma patients who receive routine cross-sectional imaging, as most nodal recurrences occur outside the node field and can be detected by both ultrasound and cross-sectional imaging.

ANNALS OF SURGICAL ONCOLOGY (2023)

添加到收藏夹
暂无数据
研讨会 海报 问题 讨论圈 基金 期刊 论文 科研社交 资讯集成 审稿人 关于我们 常见问题 移动App 隐私条款 使用条款
© Peeref 2019-2024. All rights reserved.